Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

被引：0
|
作者：
James G. Wall
Jacqueline K. Benedetti
Mark A. O'Rourke
Ronald B. Natale
John S. Macdonald
机构：
[1] Cabarrus Memorial Hospital,
[2] Southwest Oncology Group Statistical Center,undefined
[3] Ohio State University Health Center,undefined
[4] University of Southern California School of Medicine,undefined
[5] Temple University,undefined
来源：
Investigational New Drugs | 1997年 / 15卷
关键词：
hepatocellular carcinoma; topotecan; phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hepatocellular carcinoma remains a highly chemoresistant neoplasm. In this study of the topoisomerase I inhibitor topotecan a response rate of 13.9% (95% confidence interval 4.7%–29.5%) was obtained utilizing a five consecutive day bolus infusion schedule. There were no complete responses and the median survival was only eight months. Furthermore, treatment with topotecan produced significant toxicity with two-thirds of patients experiencing life-threatening (grade 4) neutropenia. When used in this dose and schedule, topotecan does not appear to be effective for patients with advanced hepatocellular carcinoma.
引用
收藏
页码：257 / 260
页数：3
相关论文
共 50 条
  • [1] Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study
    Wall, JG
    Benedetti, JK
    ORourke, MA
    Natale, RB
    Macdonald, JS
    INVESTIGATIONAL NEW DRUGS, 1997, 15 (03) : 257 - 260
  • [2] A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)
    John S. Macdonald
    Joth L. Jacobson
    Steven J Ketchel
    Geoffrey Weiss
    Sarah Taylor
    Glenn Mills
    J. Phillip Kuebler
    Saul Rivkin
    Marcel Conrad
    Investigational New Drugs, 2000, 18 : 199 - 202
  • [3] A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG 9339)
    Macdonald, JS
    Jacobson, JL
    Ketchel, SJ
    Weiss, G
    Taylor, S
    Mills, G
    Kuebler, JP
    Rivkin, S
    Conrad, M
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) : 199 - 202
  • [4] Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study
    Jacqueline K. Benedetti
    Howard A. Burris III
    Stanley P. Balcerzak
    John S. Macdonald
    Investigational New Drugs, 1997, 15 : 261 - 264
  • [5] Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study
    Benedetti, JK
    Burris, HA
    Balcerzak, SP
    Macdonald, JS
    INVESTIGATIONAL NEW DRUGS, 1997, 15 (03) : 261 - 264
  • [6] PHASE-II TRIAL OF BISANTRENE IN HEPATOCELLULAR-CARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    BROWN, TD
    FLEMING, TR
    SHILDT, RA
    COWAN, JD
    CANCER TREATMENT REPORTS, 1987, 71 (11): : 1101 - 1102
  • [7] PHASE-II TRIAL OF META-AMSA IN HEPATOCELLULAR-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BUKOWSKI, RM
    LEGHA, S
    SAIKI, J
    EYRE, HJ
    OBRYAN, R
    CANCER TREATMENT REPORTS, 1982, 66 (08): : 1651 - 1652
  • [8] A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study
    Miller, DS
    Blessing, JA
    Lentz, SS
    Waggoner, SE
    GYNECOLOGIC ONCOLOGY, 2002, 87 (03) : 247 - 251
  • [9] Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck - A phase II Southwest Oncology Group study
    Smith, RE
    Lew, D
    Rodriguez, GI
    Taylor, SA
    Schuller, D
    Ensley, JF
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 403 - 407
  • [10] Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group
    Bookman, MA
    Blessing, JA
    Hanjani, P
    Herzog, TJ
    Andersen, WA
    GYNECOLOGIC ONCOLOGY, 2000, 77 (03) : 446 - 449
12345